Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Centogene N.V. CNTG
$0.77
-$0.02 (-2.52%)
На 18:01, 12 мая 2023
+224.68%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
20801377.00000000
-
week52high
3.46
-
week52low
0.61
-
Revenue
189923000
-
P/E TTM
-1
-
Beta
-0.92926600
-
EPS
-1.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
13 июл 2023 г. в 12:30
Описание компании
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 18 июл 2022 г. |
| Credit Suisse | Outperform | Outperform | 17 июн 2021 г. |
| Credit Suisse | Outperform | 05 ноя 2020 г. | |
| Kempen & Co | Buy | 07 окт 2020 г. | |
| Evercore ISI Group | In-Line | Outperform | 24 апр 2020 г. |
| HC Wainwright & Co. | Buy | 23 ноя 2022 г. | |
| HC Wainwright & Co. | Buy | 17 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
GlobeNewsWire
07 февр 2023 г. в 06:30
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its partnering conference schedule for February 2023, with a focus on rare and genetic diseases in the lead up to Rare Disease Day (RDD) on February 28th. Since 2008, RDD has been held annually on the last day of February and includes a range of activities and initiatives throughout the month. Bringing together physicians, patient organizations, researchers, medical companies, and of course, rare disease patients from around the world, RDD raises awareness and generates change for the rare disease community.
CENTOGENE to Participate in Upcoming Conferences in December
GlobeNewsWire
01 дек 2022 г. в 06:30
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for December 2022. The Company's Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Japan. CENTOGENE invites attendees to schedule one-on-one meetings.
CENTOGENE to Participate in Upcoming Conferences in November
GlobeNewsWire
10 ноя 2022 г. в 06:30
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for November 2022. The Company's Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Spain. CENTOGENE invites attendees to schedule one-on-one meetings.
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
GlobeNewsWire
01 сент 2022 г. в 06:30
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its investment and partnering conference schedule for September 2022. Company management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York and the 9th Annual HealthTech Investment Forum (HTIF) as part of Sachs Autumn Life Sciences Week in Basel. CENTOGENE invites investors and partners to attend the presentations and schedule one-on-one meetings.